A High-Throughput Immune-Oncology Screen Identifies EGFR Inhibitors as Potent Enhancers of Antigen-Specific Cytotoxic T-lymphocyte Tumor Cell Killing
Open accessPublished version of a preprint
The DOI matches its Crossref record; 42 of the 43 references it cites were found in a registry or an index.
Abstract
We developed a screening assay in which luciferized ID8 expressing OVA was cocultured with transgenic CD8+ T cells specifically recognizing the model antigen in an H-2b–restricted manner. The assay was screened with a small-molecule library to identify compounds that inhibit or enhance T cell–mediated killing of tumor cells. Erlotinib, an EGFR inhibitor, was the top compound that enhanced T-cell killing of tumor cells. Subsequent experiments with erlotinib and additional EGFR inhibitors validated the screen results. EGFR inhibitors increased both basal and IFNγ-induced MHC class-I presentation, which enhanced recognition and lysis of tumor cell targets by CD8+ cytotoxic T lymphocytes. The ID8 cell line was also transduced to constitutively express Cas9, and a pooled CRISPR screen, utilizing the same target tumor cell/T-cell assay, identified single-guide (sg)RNAs targeting EGFR that sensitized tumor cells to T cell–mediated killing. Combination of PD-1 blockade with EGFR inhibition showed significant synergistic efficacy in a syngeneic model, further validating EGFR inhibitors as immunomodulatory agents that enhance checkpoint blockade. This assay can be screened in high-throughput with small-molecule libraries and genome-wide CRISPR/Cas9 libraries to identify both compounds and target genes, respectively, that enhance or inhibit T-cell recognition and killing of tumor cells. Retrospective analyses of squamous-cell head and neck cancer (SCCHN) patients treated with the combination of afatinib and pembrolizumab demonstrated a rate of clinical activity exceeding that of each single agent. Prospective clinical trials evaluating the combination of an EGFR inhibitor and PD-1 blockade should be conducted.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
The source backs part of the claim, not all of it — or backs it for a different population, condition or comparison.
In the citing paper
“MHC class I and II upregulation by ovarian carcinoma cells”
From Immunomodulation by targeted anticancer agents (2021) · cites this paper as Lizotte et al., 2018
Experimental — accuracy not yet measuredThe cited source says what the claim attributes to it.
In the citing paper
“In addition, various EGFRtargeting agents improve MHC class I antigen presentation by cancer cells (Lizotte et al., 2018; Pollack et al., 2011) and favor the uptake of tumor material by DCs (Banerjee et al., 2008; Nigro et al., 2019) as well as their ability to prime T cells and promote NK-cell activation in the absence of additional immunostimulatory signals (Banerjee et al., 2008; Lee et al., 2”
From Immunomodulation by targeted anticancer agents (2021) · cites this paper as Lizotte et al., 2018
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Adverse Renal Effects of Immune Checkpoint Inhibitors: A Narrative Review
Wanchoo, R., Karam, S., Uppal, N. N., Barta, V. S., Deray, G., Devoe, C., Launay-Vacher, V., Jhaveri, K. D., & on behalf of Cancer and Kidney International Network Workgroup on Immune Checkpoint Inhibitors (2017) · American Journal of Nephrology · doi:10.1159/000455014 · Cited by 15,256
Improved Survival with Ipilimumab in Patients with Metastatic Melanoma
Hodi, F. S., O'Day, S. J., McDermott, D. F., Weber, R. W., Sosman, J. A., Haanen, J. B., Gonzalez, R., Robert, C., Schadendorf, D., Hassel, J. C., et al. (2010) · New England Journal of Medicine · doi:10.1056/nejmoa1003466 · Cited by 15,155 · cited 1×
“With the FDA approval of immune checkpoint blocking antibodies, initially targeting CTLA-4 in melanoma (1) and then for PD-1/PD-L1 in melanoma (2), NSCLC (3), head and neck cancer (4), and others (5–7), the field of medical oncology has experienced a paradigm shift in treatment modalities.”
BackgroundGefitinib or Carboplatin–Paclitaxel in Pulmonary Adenocarcinoma
Mok, T. S., Wu, Y.-L., Thongprasert, S., Yang, C.-H., Chu, D.-T., Saijo, N., Sunpaweravong, P., Han, B., Margono, B., Ichinose, Y., et al. (2009) · New England Journal of Medicine · doi:10.1056/nejmoa0810699 · Cited by 8,261
Combined Nivolumab and Ipilimumab or Monotherapy in Untreated Melanoma
Larkin, J., Chiarion-Sileni, V., Gonzalez, R., Grob, J. J., Cowey, C. L., Lao, C. D., Schadendorf, D., Dummer, R., Smylie, M., Rutkowski, P., et al. (2015) · New England Journal of Medicine · doi:10.1056/nejmoa1504030 · Cited by 8,157
Self-citationNivolumab versus Everolimus in Advanced Renal-Cell Carcinoma
Motzer, R. J., Escudier, B., McDermott, D. F., George, S., Hammers, H. J., Srinivas, S., Tykodi, S. S., Sosman, J. A., Procopio, G., Plimack, E. R., et al. (2015) · New England Journal of Medicine · doi:10.1056/nejmoa1510665 · Cited by 5,807
Erlotinib in Previously Treated Non–Small-Cell Lung Cancer
Shepherd, F. A., Rodrigues Pereira, J., Ciuleanu, T., Tan, E. H., Hirsh, V., Thongprasert, S., Campos, D., Maoleekoonpiroj, S., Smylie, M., Martins, R., et al. (2005) · New England Journal of Medicine · doi:10.1056/nejmoa050753 · Cited by 5,419 · cited 4×
“With the FDA approval of immune-checkpoint blocking antibodies, initially targeting CTLA-4 in melanoma (1) and then for PD-1/PD-L1 in melanoma (2), non–small cell lung cancer (NSCLC; ref.”
BackgroundResultInfluentialNivolumab for Recurrent Squamous-Cell Carcinoma of the Head and Neck
Ferris, R. L., Blumenschein, G., Fayette, J., Guigay, J., Colevas, A. D., Licitra, L., Harrington, K., Kasper, S., Vokes, E. E., Even, C., et al. (2016) · New England Journal of Medicine · doi:10.1056/nejmoa1602252 · Cited by 5,101
Ipilimumab plus Dacarbazine for Previously Untreated Metastatic Melanoma
Robert, C., Thomas, L., Bondarenko, I., O'Day, S., Weber, J., Garbe, C., Lebbe, C., Baurain, J.-F., Testori, A., Grob, J.-J., et al. (2011) · New England Journal of Medicine · doi:10.1056/nejmoa1104621 · Cited by 4,496 · cited 1×
“Radiotherapy (9), chemotherapy (10, 11), and targeted agents, such as inhibitors ofHDACs (NCT02619253, NCT02437136), BRAF (NCT02818023), and VEGF (NCT00790010), have been or are currently being tested clinically in combinationwith immune-checkpoint blockade and have been shown to increase response rates.”
BackgroundT cell receptor antagonist peptides induce positive selection
Hogquist, K. A., Jameson, S. C., Heath, W. R., Howard, J. L., Bevan, M. J., & Carbone, F. R. (1994) · Cell · doi:10.1016/0092-8674(94)90169-4 · Cited by 2,858
Nivolumab and ipilimumab versus ipilimumab in untreated melanoma
Postow, M. A., Chesney, J., Pavlick, A. C., Robert, C., Grossmann, K., McDermott, D., Linette, G. P., Meyer, N., Giguere, J. K., Agarwala, S. S., et al. (2015) · New England Journal of Medicine · doi:10.1056/nejmoa1414428 · Cited by 2,781 · cited 2×
“With the FDA approval of immune-checkpoint blocking antibodies, initially targeting CTLA-4 in melanoma (1) and then for PD-1/PD-L1 in melanoma (2), non–small cell lung cancer (NSCLC; ref.”
Background
Cited by
Molecular targeted therapy for anticancer treatment
Min, H.-Y., & Lee, H.-Y. (2022) · Experimental & Molecular Medicine · doi:10.1038/s12276-022-00864-3 · Cited by 569
Severe immune-related adverse events are common with sequential PD-(L)1 blockade and osimertinib
Schoenfeld, A. J., Arbour, K. C., Rizvi, H., Iqbal, A. N., Gadgeel, S. M., Girshman, J., Kris, M. G., Riely, G. J., Yu, H. A., & Hellmann, M. D. (2019) · Annals of Oncology · doi:10.1093/annonc/mdz077 · Cited by 406
“Recently, EGFR-TKIs were shown to differentially enhance T-cell-mediated killing of tumor cells by increasing both basal and IFN gamma induced MHC class-I presentation [13].”
BackgroundAissa, A. F., Islam, A. B. M. M. K., Ariss, M. M., Go, C. C., Rader, A. E., Conrardy, R. D., Gajda, A. M., Rubio-Perez, C., Valyi-Nagy, K., Pasquinelli, M., et al. (2021) · Nature Communications · doi:10.1038/s41467-021-21884-z · Cited by 273
Intrinsic Immunogenicity of Small Cell Lung Carcinoma Revealed by Its Cellular Plasticity
Mahadevan, N. R., Knelson, E. H., Wolff, J. O., Vajdi, A., Saigí, M., Campisi, M., Hong, D., Thai, T. C., Piel, B., Han, S., et al. (2021) · Cancer Discovery · doi:10.1158/2159-8290.cd-20-0913 · Cited by 227
“Ovalbumin-luciferase transduction and OT-I CTL assay RPP and RPP-A cell lines were transduced to stably express OVA antigen using the pLVXlucOS-IRES-Neo lentiviral vector (32).”
BackgroundMethodInfluentialSelf-citationImmunomodulation by targeted anticancer agents
Petroni, G., Buqué, A., Zitvogel, L., Kroemer, G., & Galluzzi, L. (2021) · Cancer Cell · doi:10.1016/j.ccell.2020.11.009 · Cited by 212
Metadata
- Authors
- Lizotte, P. H., Hong, R.-L., Luster, T. A., Cavanaugh, M. E., Taus, L. J., Wang, S., Dhaneshwar, A., Mayman, N., Yang, A., Kulkarni, M., Badalucco, L., Fitzpatrick, E., Kao, H.-F., Kuraguchi, M., Bittinger, M., Kirschmeier, P. T., Gray, N. S., Barbie, D. A., & Jänne, P. A.
- Affiliations
- Dana-Farber Cancer Institute (US)
- National Taiwan University Hospital (TW)
- Harvard University (US)
- 1Belfer Center for Applied Cancer Science, Boston, Massachusetts.
- ORCID
- Venue
- Cancer Immunology Research
- Published
- 2018-12-01
- Volume
- 6
- Issue
- 12
- Pages
- 1511-1523
- ISSN
- 2326-6066 (ISSN-L)
- 2326-6074
- PMC
- PMC6601346
- OpenAlex
- W2891460256
- Cited by
- 88
- References
- 43
- Citations by year
- 2026: 4 · 2025: 12 · 2024: 12 · 2023: 12 · 2022: 15 · 2021: 12 · 2020: 12 · 2019: 9
- FWCI
- 3.10
- Type
- journal article
- Language
- en
- Open access
- green
- www.ncbi.nlm.nih.gov
- Locations
- Cancer Immunology Research (publishedVersion)
- PubMed (publishedVersion)
- PubMed Central (acceptedVersion)
- Funders
- American Cancer Society (ACS) (CRP-17-111-01-CDD)
- Foundation for the National Institutes of Health (FNIH) (U54 HL127365)
- Topics
- Health Sciences › Medicine › Oncology › Cancer Immunotherapy and Biomarkers
- Life Sciences › Immunology and Microbiology › Immunology › Immunotherapy and Immune Responses
- Life Sciences › Immunology and Microbiology › Immunology › T-cell and B-cell Immunology
- Keywords
- EGFR inhibitors, erlotinib, immune checkpoint blockade, anti-PD-1 therapy, CD8+ T cell cytotoxicity, MHC class I antigen presentation, CRISPR-Cas9 screen, small molecule screening, combination therapy, head and neck squamous cell carcinoma, pembrolizumab, afatinib, tumor immunology
- MeSH terms
- Squamous Cell Carcinoma of Head and Neck, Afatinib, Animals, Antineoplastic Combined Chemotherapy Protocols, Drug Screening Assays, Antitumor, Head and Neck Neoplasms, Humans, Mice, Inbred C57BL, T-Lymphocytes, Cytotoxic, CD8-Positive T-Lymphocytes, Coculture Techniques, Cell Line, Tumor, Protein Kinase Inhibitors, Luciferases, Firefly, High-Throughput Screening Assays, Programmed Cell Death 1 Receptor, Antibodies, Monoclonal, Humanized, CRISPR-Cas Systems, ErbB Receptors
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
How to cite
Cite CoChat for the checks on this page, and the paper for its own findings.
- This page
- CoChat. (2026). Citation check: A High-Throughput Immune-Oncology Screen Identifies EGFR Inhibitors as Potent Enhancers of Antigen-Specific Cytotoxic T-lymphocyte Tumor Cell Killing. https://app.cochat.ai/papers/10.1158/2326-6066.cir-18-0193
- The paper
- Lizotte, P. H., Hong, R.-L., Luster, T. A., Cavanaugh, M. E., Taus, L. J., Wang, S., Dhaneshwar, A., Mayman, N., Yang, A., Kulkarni, M., Badalucco, L., Fitzpatrick, E., Kao, H.-F., Kuraguchi, M., Bittinger, M., Kirschmeier, P. T., Gray, N. S., Barbie, D. A., & Jänne, P. A. (2018). A High-Throughput Immune-Oncology Screen Identifies EGFR Inhibitors as Potent Enhancers of Antigen-Specific Cytotoxic T-lymphocyte Tumor Cell Killing. Cancer Immunology Research. https://doi.org/10.1158/2326-6066.cir-18-0193
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.